Skip over main navigation
  • Sign up
  • Log in
  • Basket: (0 items)
Duchenne UK
We fund more research than anyone else
    • Search for clinical trials
    • Donate
    • Twitter
    Menu
    • About Duchenne
      • What is Duchenne
      • Diagnosing Duchenne
      • Stages Of Duchenne
      • Current Treatments
      • Supporting Therapies
      • Treatments In The Pipeline
      • Understanding Clinical Trials
      • Clinical Trial Finder
    • Patient and Parent Support
      • What to do in an emergency
      • Coronavirus Resources
      • Our message for you
      • Caring for your child
      • Resources for parents
      • Free Information Days
      • Medical Care Guidelines
      • Decipha - education support
      • Patient and Parent Stories
      • Caring during the coronavirus pandemic
    • What We Do
      • Our Mission
      • Our Impact
      • Funding Research & Trials
      • Accelerating Drug Timeline
      • Community Engagement
      • DMD Care UK
      • DMD Hub
      • Project HERCULES
      • About Us
        • Meet The Team
        • President & Patrons
        • Scientific Advisory Board
        • Patient Advisory Board
        • Donor Advisory Board
        • Trustees
        • Joining Jack
        • Alex's Wish
        • Duchenne Now
      • Watch Our Film
      • Subscribe to our PODCAST
    • Support Us
      • Duchenne Dash
      • Donate a Day
      • How You Can Help
      • Why Support Us?
      • Family and Friends Funds
      • Duchenne Direct
      • Fundraising Events
      • World's Strongest Boys
      • Corporate Support
    • News
    • Admin
      • Log in
    • Basket: (0 items)
    1. What We Do

    Duchenne UK's INNOVATE grant call

    Duchenne UK announces a Million Pound Grant Call for Research Projects for Treatments of Duchenne Muscular Dystrophy

    Duchenne UK is pleased to announce the launch of its ‘Innovate’ Grant Call, and invites proposals for funding projects up to £1million, dedicated to finding new treatments for Duchenne muscular dystrophy (DMD).

    This call is being commissioned by Duchenne UK, a patient organisation based in the UK, with a global reach. Duchenne UK has an impressive track record in supporting research aimed at accelerating effective treatments for DMD. 

    In the recent past, Duchenne UK co-funded the Phase I trial for Vamorolone, now in Phase II, and supported the development of SGT-001, the gene therapy being developed by Solid Biosciences.

    Ongoing projects range across the spectrum from pre-clinical experiments to supporting clinical trials, including developing outcome measures, and on to economic modelling and re-imbursement. 

    This call aims to identify drug development projects that are ready for trial, with compelling pre-clinical data, including data in animals, or have the potential to be in clinical trials within a 2 – 5 year timeframe.

    Funding for up to £1 million is available.

    The co-founders of Duchenne UK, Emily Crossley and Alex Johonson said: 
     
    "Supporting and accelerating innovative research is at the heart of what we do at Duchenne UK. We're particularly keen to support projects that have a clear pathway to clinical trials.”
     
     The Director of Research and Patient Engagement, Naomi Litchfield says
     
    "We are excited at the prospect of working with members of the research community with original, ground breaking ideas for treating DMD and very much look forward to seeing their proposals."
     
    How to apply:


    To apply, please send an outline proposal for the research including all relevant background information, a budget, and a milestone-driven timeline. The proposal should clearly identify the participating researchers and the location for the research. 

    Applications should be received by Friday 4th May 2018. Shortlisted applicants will be required to complete a TACT application. The successful candidates will be requested to present to TACT at the next available meeting, likely to be in July 2018.

    The TREAT-NMD Advisory Committee for Therapeutics (TACT) is a unique multi-disciplinary international group of world-recognized academic and industry drug development experts as well as representatives of patient foundations, regulators and institutional governmental scientific research centres: http://www.treat-nmd.eu/resources/tact/introduction/

     

    The proposals should be sent to Naomi Litchfield, Director of Research and Patient Engagement: [email protected] 

    NOTES FOR EDITORS 

    What is Duchenne Muscular Dystrophy?

    Duchenne Muscular Dystrophy is the most common fatal genetic disease diagnosed in childhood. Children born with DMD cannot produce the protein dystrophin which is vital for muscle strength and function. Muscle weakness starts in early childhood. Many use a wheelchair by around the age of 12. As deterioration continues it leads to paralysis and early death, often in their 20s. It almost exclusively affects boys. There is no treatment or cure. In the UK there are around 2,500 boys affected and around 300, 000 worldwide. It is classified as a rare disease.

     

    Who are Duchenne UK?

    Duchenne UK is a lean, ambitious and highly focused charity with a clear vision: to fund and accelerate treatments and a cure for Duchenne muscular dystrophy. The charity has been formed by the coming together of Joining Jack and Duchenne Children's Trust, the two biggest funders of research in the UK in the last three years. Its president is HRH The Duchess of Cornwall. Its patrons include the broadcasters Krishnan Guru-Murthy and Mary Nightingale, and the sports stars Owen Farrell, Kris Radlinski and Andy Farrell. 

     

    How to donate?

    Duchenne UK is entirely reliant on donations to fund research for treatments and a cure to DMD. This can be done via:

    • Direct Debit – Duchenne Direct
    • Individual Donation – Donate
    • If you are a family or friend affected by DMD you can set up your own fund with Duchenne UK – Family and Friend Funds
    • Take part in one of our fundraising events – Events
    • Text DUCH10 £10 to 70070
    •  

    For more information and interview requests:

    Visit www.duchenneuk.org

    Molly Hunt – Communications Manger, Duchenne UK 

    E: [email protected]

     

    Published: 31st May, 2017

    Updated: 6th December, 2017

    Author: Nick Crossley

    Related topics:
    • What We Do
    Share this page
    • Email
    • Facebook
    • Twitter
    DMD Hub

    DMD Hub

    Expanding Clinical trial capacity Read more

    Published: 1st March, 2015

    Updated: 26th June, 2019

    Author: Nick Crossley

    Related topics:
    • Accelerating Drug Development
    Attend our FREE Information Days

    Attend our FREE Information Days

    Please join us at our free Patient Information Day Read more

    Published: 27th July, 2017

    Updated: 13th October, 2020

    Author: Nick Crossley

    Comments: 1

    Related topics:
    • Community Engagement and Support
    Impact Report 2020

    Impact Report 2020

    Despite the challenges of 2020, Duchenne UK has achieved much and we hope you find the impact report that we are releasing today, uplifting. Thank you for your support and we wish you a safe and bright 2021. Read more

    Published: 23rd December, 2020

    Updated: 27th January, 2021

    Author: Nick Crossley

    Related topics:
    • News

    Latest tweet

    Sign up for our newsletter

    Please enter your first name
    Please enter your last name
    Please enter your email address Please enter a valid email address (e.g. [email protected])

    • Twitter
    • Facebook
    • Instagram
    • LinkedIn
    • Youtube

    Contact UsPrivacy Policy

    Registered Charity No. 1147094. © 2020 Duchenne UK. All rights reserved.
    A non profit company limited by guarantee. Registered in England No. 8030768

    Our mailing address is: Duchenne UK, Unit G20, Shepherd’s Building, Charecroft Way, Hammersmith, W14 0EE


    We will always store your personal details securely. We’ll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy or contact us on [email protected]